Ajooni Biotech reported a 28.2% increase in net profit to ₹432.19 lakh for the financial year ended March 31, 2026, driven by a significant rise in operational income. Revenue from operations grew 59% to ₹18,237.81 lakh from ₹11,469.19 lakh in the previous year, while total income increased to ₹18,479.62 lakh. The company’s earnings per share (EPS) for the year improved to ₹0.25 on a basic and diluted basis, up from ₹0.20 in FY25.

The Board of Directors approved the audited financial results for FY26 at a meeting held on May 28, 2026. The statutory auditors, Narinder Kumar and Company, issued an unmodified opinion on the financial statements. The audit confirmed that the company has maintained proper internal financial controls over financial reporting, which were operating effectively as of March 31, 2026.

Financial Performance

The company’s total expenses for FY26 rose to ₹17,905.79 lakh, compared to ₹11,243.16 lakh in the prior year, primarily due to higher material costs and other operational expenses. The cost of materials consumed increased to ₹14,805.33 lakh from ₹9,715.42 lakh. Despite the rise in costs, the profit before tax for the year stood at ₹573.83 lakh, up from ₹432.92 lakh in FY25.

For the quarter ended March 31, 2026, Ajooni Biotech posted a net profit of ₹94.72 lakh on revenue from operations of ₹6,062.21 lakh. This compares to a net profit of ₹154.38 lakh and revenue of ₹2,927.44 lakh in the corresponding quarter of the previous year.

Balance Sheet and Cash Flows

The company’s total assets as of March 31, 2026, stood at ₹12,036.51 lakh, an increase from ₹9,505.11 lakh a year earlier. Non-current assets, including property, plant, and equipment, were valued at ₹2,585.57 lakh. Current assets, dominated by inventories worth ₹3,945.51 lakh and trade receivables of ₹1,783.43 lakh, constituted a significant portion of the balance sheet.

Equity share capital remained unchanged at ₹3,444.87 lakh, while other equity increased to ₹5,674.27 lakh from ₹5,363.02 lakh. The company’s cash and cash equivalents decreased to ₹41.90 lakh at the end of FY26 from ₹683.02 lakh in the previous year, as reflected in the cash flow statement.

Ajooni Biotech has submitted a disclosure to the National Stock Exchange regarding the shareholding status of its promoters for the financial year ended March 31, 2026. The company confirmed that its promoters and persons acting in concert have not created any encumbrance over the shares held by them, directly or indirectly, during this period. The announcement was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011.

The disclosure, dated April 03, 2026, was submitted on behalf of all promoters. It explicitly states that no shares were encumbered during FY26. The document was signed by Jasjot Singh, the Managing Director, on behalf of the promoters. The company subsequently forwarded the yearly disclosure to the exchange on April 04, 2026, for record-keeping purposes.

Promoter Details

The filing included an annexure listing the individuals classified as promoters and members of the promoter group. The list was signed by Jasjot Singh on April 03, 2026.

Promoters

Promoter Group

The confirmation was addressed to the National Stock Exchange of India Ltd at Bandra-Kurla Complex, Mumbai. A copy of the communication was also marked to the Audit Committee of Ajooni Biotech Limited. The company’s registered office is located in Mohali, Punjab.